{"organizations": [], "uuid": "43c84301578f059e3b985d07bd3fb0bc166f7a89", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-novo-nordisk-fda-approves-update-t/brief-novo-nordisk-fda-approves-update-to-tresiba-label-to-include-devote-data-idUSFWN1R80OZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Novo Nordisk: FDA Approves Update to Tresiba Label to Include Devote data", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.017, "site_type": "news", "published": "2018-03-26T21:46:00.000+03:00", "replies_count": 0, "uuid": "43c84301578f059e3b985d07bd3fb0bc166f7a89"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-novo-nordisk-fda-approves-update-t/brief-novo-nordisk-fda-approves-update-to-tresiba-label-to-include-devote-data-idUSFWN1R80OZ", "ord_in_thread": 0, "title": "BRIEF-Novo Nordisk: FDA Approves Update to Tresiba Label to Include Devote data", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "tresiba label", "sentiment": "none"}, {"name": "copenhagen", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "brief-novo nordisk", "sentiment": "negative"}, {"name": "novo nordisk", "sentiment": "negative"}, {"name": "insulin degludec", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26 (Reuters) - Novo Nordisk:\n* U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED AN UPDATE TO US PRESCRIBING INFORMATION FOR TRESIBA (INSULIN DEGLUDEC) TO INCLUDE DATA FROM THE DEVOTE TRIAL​\n* ‍FOLLOWING INTERACTIONS WITH FDA, NOVO NORDISK HAS WITHDRAWN APPLICATIONS RELATED TO DATA FROM SWITCH TRIALS​\n* ‍”VERY PLEASED THAT FDA HAS APPROVED UPDATED LABEL FOR TRESIBA AS ONLY BASAL INSULIN TO BE LABELLED WITH A LOWER RATE OF SEVERE HYPOGLYCAEMIA COMPARED TO INSULIN GLARGINE U100,” SAYS CSO MADS KROGSGAARD THOMSEN​ Source text for Eikon: Further company coverage: (Copenhagen newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-26T21:46:00.000+03:00", "crawled": "2018-03-27T12:08:55.005+03:00", "highlightTitle": ""}